Deep sequencing reveals the spectrum of BCR-ABL1 mutations upon front-line therapy resistance in chronic myeloid leukemia: An Eastern-Indian cohort study

Dey, Samya; Basu, Soumi; Shah, Shahena; Bhattacharyya, Debmalya; Gupta, Pansi; Acharjee, Mahasweta; Roychoudhury, Susanta; Nath, Somsubhra

doi:10.1016/j.ctarc.2022.100635

Search citation statements

Order By: Relevance

Paper Sections

Select...

Discussion1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A panel of Italian clinicians and biologists suggested the indications for NGS testing for detecting BCR :: ABL1 mutations while managing patients with TKI treatment [59] . Moreover, the application of NGS has been widely used for the analysis of clonal diversity, especially CML clones with TKI resistance, and extensively used for monitoring the level of BCR :: ABL1 TKD mutations during therapy [49] , [52] , [59] , [77] , [78] , [79] . A recent multicenter study (NEXT-in-CML) found that NGS could provide a clearer picture of BCR :: ABL1 mutation status in CML patients with failure or warning responses to TKI therapy.…”

Section: Discussionmentioning

confidence: 99%